Six Ways For PD-1 Lung Cancer Programs To Differentiate
The PD-1 and PD-L1 inhibitors have delivered stellar data in a number of tumor types and hold mega-blockbuster promise – but with so many in the class, sponsors are looking to stand out. Pull-out table provides side-by-side comparison of leading programs.
You may also be interested in...
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.
PD-1 Data Promise More Shake-ups In Melanoma Standard of Care
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.
Lung-MAP Patient Screening Should Translate To Cost-Savings
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.